|
Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients |
Ramaekers BL, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DK, Grutters JP, Arriagada R, Bae K, Ball D, Baumann M, Behrendt K, Belani CP, Beresford J, Bishop J, Bonner JA, Choy H, Dahlberg SE, De Ruysscher D, Dische S, Fournel P, Koch R, Le Pechoux C, Mandrekar SJ, Mauguen A, Mornex F, Nankivell M, Nelson G, Parmar MK, Paulus R, Pignon JP, Saunders MI, Sause W, Schild SE, Turrisi AT, Zajusz A |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Ramaekers BL, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DK, Grutters JP, Arriagada R, Bae K, Ball D, Baumann M, Behrendt K, Belani CP, Beresford J, Bishop J, Bonner JA, Choy H, Dahlberg SE, De Ruysscher D, Dische S, Fournel P, Koch R, Le Pechoux C, Mandrekar SJ, Mauguen A, Mornex F, Nankivell M, Nelson G, Parmar MK, Paulus R, Pignon JP, Saunders MI, Sause W, Schild SE, Turrisi AT, Zajusz A. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. Journal of Thoracic Oncology 2013; 8(10): 1295-307 Indexing Status Subject indexing assigned by NLM MeSH Aged; Carcinoma, Non-Small-Cell Lung /economics /mortality /pathology /radiotherapy; Carcinoma, Squamous Cell /economics /mortality /pathology /radiotherapy; Cost-Benefit Analysis; Dose Fractionation; Female; Follow-Up Studies; Humans; Lung Neoplasms /economics /mortality /pathology /radiotherapy; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Neoplasm Recurrence, Local /economics /mortality /pathology /radiotherapy; Neoplasm Staging; Prognosis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate AccessionNumber 22014006022 Date bibliographic record published 30/04/2014 |
|
|
|